Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
An open-label, Phase 1/2 study of HPN328 as monotherapy to assess the safety, tolerability
and PK in patients with advanced cancers associated with expression of DLL3.